home / stock / tlsa / tlsa quote
Last: | $0.859 |
---|---|
Change Percent: | -2.97% |
Open: | $0.9119 |
Close: | $0.859 |
High: | $0.92 |
Low: | $0.8486 |
Volume: | 178,512 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.859 | $0.9119 | $0.859 | $0.92 | $0.8486 | 178,512 | 07-02-2024 |
$0.8856 | $0.948 | $0.8856 | $0.948 | $0.87 | 50,185 | 07-01-2024 |
$0.919 | $0.882 | $0.919 | $1.04 | $0.85 | 385,403 | 06-28-2024 |
$0.88 | $0.92 | $0.88 | $0.975 | $0.85 | 225,603 | 06-27-2024 |
$0.9273 | $0.93 | $0.9273 | $0.99 | $0.89 | 224,189 | 06-26-2024 |
$0.97 | $0.92 | $0.97 | $1 | $0.9 | 415,791 | 06-25-2024 |
$0.948 | $0.8726 | $0.948 | $0.97 | $0.8483 | 424,852 | 06-24-2024 |
$0.8 | $0.7867 | $0.8 | $0.83 | $0.76 | 133,450 | 06-21-2024 |
$0.7867 | $0.7 | $0.7867 | $0.7871 | $0.665 | 162,085 | 06-20-2024 |
$0.72 | $0.7952 | $0.72 | $0.7952 | $0.72 | 67,483 | 06-19-2024 |
$0.72 | $0.7952 | $0.72 | $0.7952 | $0.72 | 67,483 | 06-18-2024 |
$0.79 | $0.7426 | $0.79 | $0.81 | $0.74 | 122,358 | 06-17-2024 |
$0.74 | $0.701 | $0.74 | $0.78 | $0.7 | 87,394 | 06-14-2024 |
$0.728 | $0.77 | $0.728 | $0.8427 | $0.7 | 285,083 | 06-13-2024 |
$0.8161 | $0.92 | $0.8161 | $0.9498 | $0.7715 | 316,469 | 06-12-2024 |
$0.99 | $0.94 | $0.99 | $1.025 | $0.86 | 510,835 | 06-11-2024 |
$0.9999 | $1 | $0.9999 | $1 | $0.9177 | 455,315 | 06-10-2024 |
$1 | $1 | $1 | $1.03 | $0.9506 | 257,488 | 06-07-2024 |
$1 | $1.03 | $1 | $1.05 | $0.91 | 614,131 | 06-06-2024 |
$1.01 | $1.02 | $1.01 | $1.05 | $0.98 | 397,288 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tiziana Life Sciences plc Company Name:
TLSA Stock Symbol:
NASDAQ Market:
Tiziana Life Sciences plc Website:
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced t...
--News Direct-- Tiziana Life Sciences Ltd (NASDAQ:TLSA) chairman and CEO Gabriele Cerrone joined Proactive's Stephen Gunnion with more details of the company's recent advancements and news. Tiziana Life Sciences is developing a fully human CD3 monoclonal antibody, delivered intranasally, ...
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Dru...